Apoptosis resistance is crucially involved in cancer development and progression, represents the leading cause for failure of anticancer therapy and is caused, for example, by downregulation of proapoptotic intracellular signaling molecules such as caspase-8. We found that the cytotoxic drugs methotrexate (MTX) and 5-fluorouracil (5-FU) were both able to sensitize resistant tumor cells for induction of apoptosis by p53-mediated upregulation of caspase-8. Increase in caspase-8 messenger RNA and protein expression disabled tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced proliferation and restored sensitivity toward TRAIL-induced apoptosis which was inhibited by transfection of p53 decoy oligonucleotides, p53 shRNA and caspase-8 shRNA. Upregulation of caspase-8 and sensitization toward TRAIL-induced apoptosis was found both in a broad panel of tumor cell lines with downregulated caspase-8 and in TRAIL-resistant primary tumor cells of children with acute leukemia. Taken together, we have identified caspase-8 as an important p53 target gene regulated by cytotoxic drugs. These findings highlight a new druginduced modulation of physiological apoptosis pathways, which may be involved in successful anticancer therapy using MTX and 5-FU in leukemia and solid tumors over decades.
Introduction
Resistance of tumor cells against induction of apoptosis leads to failure of antitumor therapy by cytotoxic drugs or irradiation and to impaired prognosis of patients (Debatin and Krammer, 2004) . Apoptosis resistance can be caused by alterations in the intracellular apoptosis signaling pathway such as downregulation of proapoptotic signaling molecules like caspase-8. Downregulation of caspase-8 is frequent in tumors of different origin, is mostly caused by promoter hypermethylation and leads to enhanced tumor progression and unfavorable prognosis of patients (Pingoud-Meier et al., 2003) . We therefore studied methods to upregulate caspase-8 expression in tumor cells.
To upregulate caspase-8, we tried to activate the caspase-8 promoter. Structural analyses of the promoter region of caspase-8 identified binding sites for p53, nuclear factor-kB (NF-kB), AP-1, SP-1, IRF-1 and Ets-like transcription factors (Liedtke et al., 2003) .
p53 is an important mediator of the intrinsic apoptosis signaling pathway that is activated by cytotoxic drugs and irradiation, and plays a key role in signal transcription, cell cycle arrest and apoptosis (Blagosklonny, 2002; Fuster et al., 2007) . p53 is mutated and dysfunctional in many tumors leading to impaired prognosis although some forms of mutated p53 retain transcriptional activity (Olivier et al., 2002; Resnick and Inga, 2003; Joerger and Fersht, 2007; Strano et al., 2007) .
For readout of caspase-8 function, we used tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. TRAIL is a member of the tumor-necrosis factor family that induces apoptosis in tumor cells via the extrinsic signaling pathway upon binding to its death receptors TRAIL-R1 and -R2. Caspase-8 binds as the most apical caspase to the TRAIL receptors as part of the death-inducing signaling complex. Downregulation of caspase-8 is associated with resistance against TRAIL-induced apoptosis accompanied by TRAIL-induced proliferation of tumor cells (Ehrhardt et al., 2003; Baader et al., 2005) .
Various links exist between the intrinsic apoptosis signaling pathway and the extrinsic pathway activated by TRAIL. Cytotoxic drugs were shown to enhance TRAIL-induced apoptosis by different mechanisms including p53-mediated upregulation of the TRAILreceptors TRAIL-R1 and -R2 (Ö zo¨ren and El-Deiry, 2003; Gomez-Lazaro et al., 2004; Wang and El-Deiry, 2003a, b) , while caspase-8 was not yet described in this context. We therefore asked whether cytotoxic drugs might be able to upregulate caspase-8.
Results
Downregulation of caspase-8 is frequent in tumor cells leading to resistance against induction of apoptosis and unfavorable prognosis of patients (Pingoud-Meier et al., 2003) . To study apoptosis resistance due to downregulation of caspase-8, we used several tumor cell lines with constitutive downregulation of caspase-8 expression including the Ewing sarcoma cell line CADO, the neuroblastoma cell line Kelly, the medulloblastoma cell line D425 and the glioblastoma cell line U373 (Fulda and Debatin, 2002; Ashley et al., 2005 ; western blot in Figure 1a ). Two additional cell lines were used with accompanied downregulation of caspase-8 expression: J-TR cells and CEM-TR cells represent derivative cell lines with lost expression of caspase-8 obtained from Jurkat and CEM cells, respectively (Ehrhardt et al., 2003) .
MTX-induced upregulation of caspase-8 and sensitization for TRAIL-induced apoptosis
Up to now, interferon-g and azacytidine were shown to upregulate caspase-8 (Teitz et al., 2000; Fulda and Debatin, 2002) , but both substances show limited antitumor activity and do not participate in most actual polychemotherapy protocols. In search for additional agents upregulating caspase-8 in tumor cells with no or low expression of caspase-8, we tested common cytotoxic drugs successfully used in clinical practice over decades (data not shown). When methotrexate (MTX) was added to tumor cell lines with downregulated caspase-8, expression of caspase-8 was upregulated significantly (western blot in Figure 1a) .
To test the functionality of upregulated caspase-8, we used TRAIL as stimulants as apoptosis induction by TRAIL is highly dependent on the expression of caspase-8. In addition, TRAIL induces proliferation in tumor cells lacking caspase-8 which should be avoided during therapy with TRAIL (Ehrhardt et al., 2003) , for example, by upregulation of caspase-8. Upregulation of caspase-8, even in low amounts, was accompanied by gain of sensitivity toward TRAIL-induced apoptosis in many cell lines (Figure 1a ). In contrast, other cell lines did not show significant sensitization for TRAIL-induced apoptosis despite of upregulation of high amounts of caspase-8 (Supplementary Figure 1) , suggesting the presence of additional antiapoptotic factors.
In addition to cell lines, primary tumor cells of children (n ¼ 66) with acute leukemia were analysed in vitro and MTX was used in plasma peak concentration due to apoptosis resistance of primary cells and short incubation periods. Forty-two children (64%) were resistant toward TRAIL-induced apoptosis and MTX at plasma peak concentration enabled TRAIL-induced apoptosis in 14/42 (33%) of TRAIL-resistant primary samples (Figures 1b and c) although the molecular mechanism could not be studied in primary cells due to sample volume limitations.
Role of caspase-8 in MTX-induced sensitization for TRAIL-induced apoptosis To study the mechanism of MTX-induced upregulation of caspase-8, we started using the cell line J-TR. Downregulation of caspase-8 was responsible for resistance against TRAIL-induced apoptosis as upregulation of caspase-8 expression by interferon-g or transfection of the caspase-8 gene enabled apoptosis induction by TRAIL (Figures 2a-c shown for CEM-TR Supplementary Figure 2) . As low amounts of caspase-8 expression allowed apoptosis induction by TRAIL, loss of caspase-8 might represent the unique mechanism of TRAIL resistance in these cells. In J-TR cells, expression of caspase-8 was upregulated on both mRNA and protein level accompanied by TRAIL-induced apoptosis (Figures 2d and e) .
Upregulation of caspase-8 expression and sensitization for TRAIL-induced apoptosis was time and dose dependent (Figures 2f-g ), but independent from the preparation of TRAIL as monomer or trimer (data not shown). Upregulation of caspase-8 prevented TRAILmediated proliferation and survival in all tumor cell lines tested (data not shown). Similarly, cells were sensitized toward apoptosis induction by Apo-1 triggering the CD95/Apo-1/Fas system (data not shown). In contrast, further intracellular apoptosis signaling molecules and regulators were not regulated by MTX (Supplementary Figure 3) .
The irreversible caspase-8-specific inhibitor zIETDfmk and the protein neosynthesis inhibitor cycloheximide strongly reduced MTX-mediated sensitivity toward TRAIL-induced apoptosis (Supplementary Figure 4A , data not shown). As shown in J-TR, CEM-TR, CADO and U373 cells, sensitization toward TRAIL-induced apoptosis by MTX highly depended on upregulation of caspase-8 as it was inhibited by transfection of shRNA against caspase-8 (Figure 3 ).
Role of p53 in MTX-induced sensitization for TRAIL-induced apoptosis To investigate the mechanism leading to upregulation of caspase-8 and TRAIL sensitivity, J-TR cells were used to study the activation of the transcription factors p53, NF-kB, AP-1, SP-1, IRF-1 and Ets-like transcription factors which are all known to bind to the caspase-8 promoter (Liedtke et al., 2003) (Figure 4a and Supplementary Figure 4B ). Western blot analysis revealed MTX-induced accumulation of p53 in wild-type conformation using a conformation-specific antibody (Milner et al., 1987) (Figure 4a ). Indicating transcriptional activity of p53 in J-TR cells, two p53-dependent proteins were upregulated by MTX: p21 and MDM2 (Figure 4b ). In parallel to MTX, other p53-stimulating agents like glycerol (Ohnishi et al., 1999) , peptide 46 (Bykov et al., 2002) and p53 reactivation and induction of massive apoptosis 1 (PRIMA-1) (Selivanova et al., 1997) Primary acute leukemia samples from 66 children were stimulated with MTX (10 mM) and TRAIL (Pepro, 1 mg/ml) as described in 'Materials and methods'. Of these, 42 samples were resistant against TRAIL-induced apoptosis (specific apoptosis by TRAIL o5%). Depicted are 14/42 samples where MTX sensitized for TRAIL-induced apoptosis. (c) Data of (b) are presented as dot plot. Statistical analysis was performed using one-way RM ANOVA on ranks showing median and range (25-75th percentile). Apoptosis was measured using forwardside scatter analysis for leukemia cells and DNA fragmentation for adherent cells in FACscan. Western blot was performed as described in 'Materials and methods'. Data are presented as mean7s.e.m. of at least three independent experiments. *Po0.05, ANOVA, for multivariate analysis each substance alone compared to the combination of two; NS, not significant.
p53-mediated upregulation of caspase-8 H Ehrhardt et al
induction by MTX alone in these cells (Supplementary Figure 5B ). p53 activity was inhibited using p53 decoy oligonucleotides containing the DNA-binding domain of p53, covering and inhibiting active p53, which disabled both upregulation of caspase-8 and TRAIL-induced apoptosis (data not shown). Similarly, transfection of shRNA for p53 completely disabled MTX-induced sensitization for TRAIL-induced apoptosis in all cell lines tested (Figure 4c ), suggesting an important role of p53 for the effect of MTX on apoptosis sensitivity.
MTX-induced, p53-independent upregulation of TRAIL death receptors
The most prominent p53-regulated signaling molecules within the TRAIL apoptosis signaling pathway are known to be the TRAIL-receptors, especially TRAIL-R2 (Ö zo¨ren and El-Deiry, 2003) . MTX upregulated TRAIL-R1 and -R2 in J-TR cells (Figure 5a ). To our surprise, upregulation of the death receptors TRAIL-R1 and -R2 by MTX occurred independently from p53 in J-TR cells (Figure 5b , similar data for p53 decoy transfection not shown) excluding that the (f and g) J-TR cells were stimulated with MTX as indicated for 48 h followed by TRAIL (30 ng/ml) for additional 24 h (f) or J-TR were preincubated with MTX (10 nM) for time periods indicated and TRAIL (30 ng/ml) was added for additional 24 h before determination of apoptosis induction (g). Apoptosis measurement and presentation, western blot and statistical analysis were performed as in Figure 1 . 
Discussion
Resistance against induction of apoptosis is a major challenge for anticancer therapy, and downregulation of caspase-8 represents a clinically relevant mechanism for apoptosis resistance in tumor cells (Pingoud-Meier et al., 2003) . Here, we report for the first time that anticancer drugs like MTX und 5-FU were able to overcome apoptosis resistance by p53-mediated upregulation of caspase-8. This conclusion is supported by two lines of evidence: (1) caspase-8 shRNA disabled MTXinduced sensitization for TRAIL-induced apoptosis and (2) inhibition of p53 by p53 decoy oligonucleotides or p53 shRNA disabled upregulation of caspase-8 and MTX-induced sensitization for TRAIL-induced apoptosis. As MTX-and 5-FU-induced sensitization for TRAIL-induced apoptosis was found in a broad range of tumor cell lines and in primary tumor cells, p53-mediated upregulation of caspase-8 might represent a widespread, yet unknown proapoptotic mechanism activated by cytotoxic drugs.
Surface expression of TRAIL death receptors TRAIL-R1 and -R2 was increased by MTX, and TRAIL-R1 and -R2 represent the most prominent p53-regulated molecules in the TRAIL apoptosis signaling pathway (Ö zo¨ren and El-Deiry, 2003) . Upregulation of either TRAIL-R1 or -R2 was shown to facilitate TRAIL-induced apoptosis in various cell lines (Shankar and Srivastava, 2004) . Therefore, we were surprised to find upregulation of TRAIL-R1 and -R2 by MTX independently from p53 (Figures 5a-b , data not shown), suggesting cell type-specific signaling. These data are in accordance with results showing p53-independent upregulation of TRAIL death receptors (Meng and El-Deiry, 2001 ). Induction of apoptosis by MTX or 5-FU alone in the low-toxic concentrations used was not influenced by transfection of shRNA caspase-8 or shRNA p53, suggesting p53-and caspase-8-independent apoptosis signaling by the cytotoxic drugs alone under these conditions. Over time, various sub-cell lines emerged out of the original Jurkat and CEM cell lines which exhibit different heterozygous point missense mutations of p53 with unknown transcriptional activity (Olivier et al., 2002) . Within the complex regulation of p53, certain missense mutations of p53 were shown to retain p53 transcriptional activity (Olivier et al., 2002; Resnick and Inga, 2003; Joerger and Fersht, 2007) mainly for two reasons: (1) intact DNA-binding site and (2) restoration of wild-type conformation of p53. When the p53 gene was sequenced, both our J-TR and CEM-TR cells did not reveal p53 mutations in the binding regions of exons 4-9 (data not shown). Wild-type conformation and function of p53 in J-TR and CEM-TR cells was further shown by western blot using a wild typespecific antibody (Milner et al., 1987) and by upregulation of the typical p53 target genes p21 and MDM2 (Figures 4a-b , data not shown). Therefore, p53 retained transcriptional activity in both our J-TR and CEM-TR cells. Cytotoxic drugs are able to induce p53-dependent upregulation of caspase-8 and increase apoptosis sensitivity in tumor cells with wild-type p53 or mutant forms of p53 with intact transcriptional activity.
A p53-inducible element downstream of the transcriptional start site of the caspase-8 promoter was identified recently which was responsible for inducible, but not for baseline activity of the promoter (Liedtke et al., 2003) . Our data suggest that caspase-8 should be studied in more detail in the context of p53-mediated sensitivity for TRAIL-induced apoptosis, as upregulation of caspase-8 might participate to apoptosis sensitivity in addition to upregulation of TRAIL-R1 and -R2. As we show that cytotoxic drugs upregulate caspase-8 and caspase-8 acts as an apical caspase in the context of death receptor-induced apoptosis, we detected a new link between the intrinsic and the extrinsic apoptosis signaling pathways.
Most importantly, we recently described that downregulation of caspase-8 induced a new biological outcome upon stimulation with TRAIL: TRAIL induced proliferation in tumor cells with loss of caspase-8 expression (Ehrhardt et al., 2003; Baader et al., 2005) . These data suggested that patients with tumor cells proliferating upon stimulation with TRAIL, the socalled group P tumor cells, should be excluded from potential therapy with TRAIL. In contrast, the data presented here show that cytotoxic drugs like MTX and 5-FU might enable therapy with TRAIL in patients with group P tumor cells with downregulation of caspase-8, as they both resensitize these tumor cells for (Figures 1a, 6a , data not shown). Our data support an inclusion of TRAIL into polychemotherapy protocols in close proximity to the use of MTX or 5-FU, which should be further evaluated in preclinical and clinical trials.
Downregulation of caspase-8 is accompanied by impaired prognosis of cancer patients (Pingoud-Meier et al., 2003) , suggesting an important role of caspase-8 not only in apoptosis activated by death receptors, but also in the intrinsic apoptosis signaling pathway. Downregulation of caspase-8 is due to epigenetic regulatory mechanisms like hypermethylation, mutations or loss of the caspase-8 gene. Demethylation by azacytidine or activation of the STAT-1/IRF-1 pathway by interferon-g induced reexpression of caspase-8 (Teitz et al., 2000; Fulda and Debatin, 2002) . Here, we show a new mechanism for reexpression of caspase-8-drug-induced accumulation of p53. In contrast to azacytidine and interferon-g, p53-activating cytotoxic drugs like MTX or 5-FU are broadly used in anticancer therapy. These cytotoxic drugs might enable apoptosis in tumor cells by upregulation of caspase-8, which might represent an important new mechanism responsible for the successful use of these well-proven drugs in anticancer therapy for decades.
Materials and methods

Materials
Three different preparations of TRAIL were used giving similar results: TRAIL without his-tag produced in Escherichia coli (Peprotech, Tebu-bio, Offenbach, Germany; this form of TRAIL was used exclusively in primary leukemia cells), with his-tag produced in Pichia pastoris (Jeremias et al., 1998) and with his-tag produced in E. coli and multimerized (Alexis Corp., Gru¨nberg, Germany; this form of TRAIL was used in most experiments with cell lines). zIETD, MTX, 5-FU, PRIMA-1 and pifithrin-a were obtained from Calbiochem (San Diego, CA, USA), doxorubicin from Baxter oncology GmbH (Frankfurt, Germany), all further reagents were obtained from Sigma (Deisenhofen, Germany). Antibodies for TRAIL receptor TRAIL-R1 and -R2 analysis by FACscan were obtained from Alexis Corp. For western blot, the following antibodies were used: anti a-tubulin from Oncogene (San Diego, CA, USA), anti-Histon H1, anti MDM-1, antip21 and anti-p53 (DO-1) from Santa Cruz Biotechnologies (Santa Cruz, CA, USA), anti-p53 (Ab-5) from Calbiochem (San Diego, CA, USA) and anti-caspase-8 from Alexis Corp (Gru¨nberg, Germany).
Cell culture, primary cells, TRAIL receptor expression and apoptosis assays U373 cells were a kind gift by Christel Herold-Mende (Neurosurgery, Heidelberg, Germany), Sy5y were obtained by DSMZ (Braunschweig, Germany), all further cell lines have been published before (Fulda and Debatin, 2002; Ehrhardt et al., 2003) and were maintained as described there.
For all cell line experiments, cells were seeded at 0.25 Â 10 6 / ml for leukemic cells and at 0.05 Â 10 6 /ml for adherent cells, and incubated with cytotoxic drugs for 48 h for leukemia cells and 72 h for adherent cells followed by TRAIL Alexis (30 ng/ml) for additional 24 h. Apoptosis was measured by forwardside scatter analysis or Nicoletti staining using FACscan (Becton Dickinson, Heidelberg, Germany). For inhibition experiments, cell lines were pretreated for 4 h before stimulation. The reversible p53 inhibitor pifithrin-a was applied daily.
For detection of TRAIL receptor expression, cells were stained with TRAIL-R1 or -R2 or isotype control for 30 min at 41C followed by biotinylated rabbit anti-mouse F(ab)2 (Dako, Glostrup, Denmark) and Streptavidin (Dako).
Primary leukemia blasts were obtained from children (n ¼ 66) treated for acute leukemia at the Ludwig Maximilians University's children's hospital during [2001] [2002] [2003] [2004] . Samples were obtained by bone marrow puncture at initial diagnosis or diagnosis of relapse before onset of therapy and isolated using Ficoll Isopaque (Amersham, Uppsala, Sweden). Primary leukemia samples were seeded at 1.0 Â 10 6 /ml and were stimulated simultaneously with MTX (10 mM) and TRAIL Pepro (1 mg/ml). Apoptosis was measured by forwardside scatter analysis after 24 h, if spontaneous apoptosis was above 40%, otherwise after 48 h. TRAIL resistance was defined as specific apoptosis by TRAIL o5%.
Quantitative real-time PCR and western blot analysis Quantitative real-time PCR was performed as described (Baader et al., 2005) , caspase-8 primers were: fw, 5 0 -cactagaaaggaggagatggaaag-3 0 ; rev, 5 0 -ctatcctgttctcttggagagtcc-3 0 and the housekeeping gene hrpt fw, 5 0 -ggtggagatgatctctcaactttaa-3 0 ; hrpt bw, 5 0 -aggaaagcaaagtctgcattgtt-3 0 (Metabion, Munich, Germany).
Western blot analysis of total cellular protein was performed as described (Ehrhardt et al., 2003) . For nuclear extracts, cells were lysed using 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.0, 1 mM KCl, 1.5 mM MgCl 2 , 0.5% Triton-X supplemented with proteinase inhibitors aprotinin, dichloro-diphenyl-trichloroethane, leupeptin and phenylmethylsulfonyl fluoride followed by lysis of cell nuclei by 20 mM HEPES, pH 7.9, 400 mM KCl, 0.1 mM ethylenediaminetetraacetic acid, 25% glycerin. For evaluation of wildtype p53 conformation, immunoprecipitation of wild-type p53 was performed in the absence of denaturating agents using sepharose beads (Sigma) and anti-p53 Ab-5 antibody and precipitate was analysed using anti-p53 (DO-1) antibody. For quantification of western blots, AIDA Image Analyzer was used.
Plasmids and transfection experiments
For vector-expressing shRNAs against caspase-8, oligos contained the target sequence used by Wagner et al. (2004) (5 0 -gggtcatgctctatcagat-3 0 ) and had the following sequence: fw, 5 0 -gatctcgggtcatgctctatcagatttcaagagaatctgatagagcatgaccctttttggaaa-3 0 and rev, 5 0 -agcttttccaaaaagggtcatgctctatcagattctcttgaaatctgatagagcatgacccga-3 0 . Oligos were annealed and cloned into the pTER vector (van de Wetering et al., 2003) using BglII and HindIII. Furthermore, caspase-8 expression plasmid (Muzio et al., 1996) and shRNA for p53 (Brummelkamp et al., 2002) cloned into pRETRO (Oligoengine, Seattle, WA, USA) were used. J-TR cells were transfected using the Cell Line Nucleofactor kit V (Amaxa Inc., Gaithersburg, MD, USA) according to the manufacturer's instructions. For transient transfection experiments, cells were stimulated as indicated 6 h after transfection.
Statistical analysis
Specific apoptosis was calculated as described (Ehrhardt et al., 2004) . For cell line experiments, data are presented as mean values of at least three independent experiments7s.e.m. if not p53-mediated upregulation of caspase-8 H Ehrhardt et al stated differently. All cell line experiments were performed in duplicates and standard deviation was o5% within each experiment. To test for statistically significant differences, paired t-test was applied, for multivariate analysis one-way repeated measures analysis of variance (RM ANOVA) was used. Primary samples were evaluated using one-way RM ANOVA on ranks. Statistical significance was accepted with P-values o0.05.
